Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis
Journal of Experimental Medicine · 06.01.2025 · 222 (1)
DOI: 10.1084/jem.20240957 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 27.11.2024. Verfasst von Arja Ray und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of California, San Francisco, CA, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Killer Cells, Natural, Lectins, C-Type, Receptors, Cell Surface. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NCI NIH HHS, Jean Perkins Foundation, Cancer Research Institute.
Abstract (Originalsprache)
CD206 is a common marker of a putative immunosuppressive “M2” state in tumor-associated macrophages (TAMs). We made a novel conditional CD206 (Mrc1) knock-in mouse to specifically visualize and/or deplete CD206+ TAMs. Early depletion of CD206+ macrophages and monocytes (Mono/Macs) led to the indirect loss of conventional type I dendritic cells (cDC1), CD8 T cells, and NK cells in tumors. CD206+ TAMs robustly expressed CXCL9, contrasting with stress-responsive Spp1-expressing TAMs and immature monocytes, which became prominent with early depletion. CD206+ TAMs differentially attracted activated CD8 T cells, and the NK and CD8 T cells in CD206-depleted tumors were deficient in Cxcr3 and cDC1-supportive Xcl1 and Flt3l expressions. Disrupting this key antitumor axis decreased tumor control by antigen-specific T cells in mice. In human cancers, a CD206Replete, but not a CD206Depleted Mono/Mac gene signature correlated robustly with CD8 T cell, cDC1, and NK signatures and was associated with better survival. These findings negate the unqualified classification of CD206+ “M2-like” macrophages as immunosuppressive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of California, San Francisco, CA, USA.
- ImmunoX Initiative, University of California, San Francisco, CA, USA.
- UCSF CoLabs, University of California, San Francisco, CA, USA.
- Department of Medicine, University of California, San Francisco, CA, USA.
ORCID-Profile: Arja Ray, Kenneth H Hu, Kelly Kersten, Tristan Courau, Nicholas F Kuhn, Itzia Zaleta-Linares, Bushra Samad, Alexis J Combes, Matthew F Krummel
Förderung
- NCI NIH HHS
- Jean Perkins Foundation
- Cancer Research Institute
- NIH HHS
- American Cancer Society
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Ray, A., Hu, K. H., Kersten, K., Courau, T., Kuhn, N. F., Zaleta-Linares, I., Samad, B., Combes, A. J., & Krummel, M. F. (2025). Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis. Journal of Experimental Medicine, 222(1). https://doi.org/10.1084/jem.20240957
Vancouver
Ray A, Hu KH, Kersten K, Courau T, Kuhn NF, Zaleta-Linares I, et al. Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis. Journal of Experimental Medicine. 2025;222(1). doi:10.1084/jem.20240957
BibTeX
@article{Ray2025,
author = {Ray, Arja and Hu, Kenneth H and Kersten, Kelly and Courau, Tristan and Kuhn, Nicholas F and Zaleta-Linares, Itzia and Samad, Bushra and Combes, Alexis J and Krummel, Matthew F},
title = {Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis},
journal = {Journal of Experimental Medicine},
year = {2025},
volume = {222},
number = {1},
doi = {10.1084/jem.20240957}
}
EUVIMED